This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.
Stay up to date on recent advances in oncology nursing and patient care.
SUD, Remote Monitoring Appear Feasible for Outpatient BiTE in MM
Step-up dosing with remote monitoring resulted in 47% of patients receiving bispecific antibodies remaining outpatient, even in cases of CRS.
Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies
Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.
FDA Relaxes REMS, Monitoring Rules for Liso-Cel and Ide-Cel
The FDA removed REMS and reduced certain monitoring needs for liso-cel and ide-cel in B-cell malignancies.
Beth Faiman Discusses Recent Changes in Multiple Myeloma Treatment Landscape
Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.
Q&A: Subcutaneous Daratumumab Eases Myeloma Time Burden
Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C.
Subcutaneous Daratumumab Could Mark First Smoldering Myeloma Treatment
Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma. Here’s what nurses should know.
Understanding How On-Target and Off-Target ADC Toxicities Work
Monitoring for Infection-Like AEs Is Essential for CIML NK in GI Cancers
Belzutifan May Lengthen Quality-Adjusted Survival in Advanced RCC
KIM-1 Biomarker May Be Prognostic of Response, Outcomes in RCC